Results 71 to 80 of about 12,732 (162)
Heliyon, 2021 Arenaviral infections often result lethal hemorrhagic fevers, affecting primarily in African and South American regions. To date, there is no FDA-approved licensed vaccine against arenaviruses and treatments have been limited to supportive therapy. Hence,
Kazi Faizul Azim +6 more
doaj +1 more source
Strategic Preparedness of Broad‐Spectrum Antivirals for Rapid Response Towards Next Pandemics
Small Science, Volume 6, Issue 1, January 2026.Nanoengineered broad‐spectrum antivirals (BSAs) represent a transformative approach to pandemic preparedness. Unlike virus‐specific drugs requiring separate development, BSAs act across multiple viral families through nanoengineering strategies that enhance solubility, bioavailability, and host‐targeted activity.
Sanoj Rejinold N +2 more
wiley +1 more source
Advances in Virology, Volume 2018, Issue 1, 2018., 2018 Advances in the next generation sequencing (NGS) technologies have significantly increased our ability to detect new viral pathogens and systematically determine the spectrum of viruses prevalent in various biological samples. In addition, this approach has also helped in establishing the associations of viromes with many diseases.
Andrey A. Ayginin +10 more
wiley +1 more source
Eco-épidémiologie des mammarenavirus à l’interface rongeur-humain au Mozambique
, 2022 Emerging infectious diseases (EIDs) have been a major global concern and more than 70% of new EIDs are zoonotic diseases that mostly originated from wildlife.
Mapaco, Lourenço
core +1 more source
, 2022 International audienceLCMV RNA has been detected both in its natural host reservoir, the house mouse Mus musculus, and other rodent species in Gabon. In addition, many pathogenic and nonpathogenic Mammarenavirus reservoirs are also present in the country;
Boundenga, Larson +7 more
core +1 more source
Pathogens, 2020 Lassa virus (LASV) is a mammarenavirus (arenavirus) that causes zoonotic infection in humans that can lead to fatal hemorrhagic Lassa fever (LF) disease. Currently, there are no FDA-approved vaccines or therapeutics against LASV.
Wun-Ju Shieh +4 more
doaj +1 more source
Partitioning Social and Spatial Drivers of Infection Risk
Ecology and Evolution, Volume 15, Issue 11, November 2025.Contact rates drive disease spread, yet are often oversimplified as uniform across individuals. Using data on Mastomys natalensis, we show that exposure to Morogoro virus is linked to spatial overlap with infected conspecifics, but not overall overlap, and that direct contact occurs with only a few individuals despite broad home range overlap ...
L. Kirkpatrick +4 more
wiley +1 more source
Ecologic Traits Analysis for Identifying Rodent Hosts for Arenavirus and Hepacivirus in the Americas
Biotropica, Volume 57, Issue 6, November 2025.Over half of emerging human pathogens originate from wildlife, with rodents serving as key zoonotic hosts. This study used ecological trait‐based models to identify rodent traits associated with arenavirus and hepacivirus infections and detect potential host species across the Americas, our models achieve high predictive accuracy (AUC = 0.92–0.96).
María del Carmen Villalobos‐Segura +3 more
wiley +1 more source
, 2023 Lassa fever (LF) is a potentially lethal viral haemorrhagic infection of humans caused by Lassa mammarenavirus (LASV). It is an important endemic zoonotic disease in West Africa with growing evidence for increasing frequency and sizes of outbreaks ...
Ntoumi, Francine +11 more
core +2 more sources
Virulence, 2020 Arenaviruses, such as Lassa virus (LASV), can cause severe and fatal hemorrhagic fevers (e.g., Lassa fever, LF) in humans with no vaccines or therapeutics.
Shuiyun Lan +5 more
doaj +1 more source